Grants and Contributions:
The direct and immediate benefit of the project's first stage is the rapid development of a plant-based vaccine that may lead to an effective vaccine for COVID-19. The second stage, building a GMP facility that can manufacture vaccine and antibodies, is expected to increase biomanufacturing capabilities and build on areas of strength and technological advantage to advance Canada’s life sciences industry. This project anticipates to maintain 275 full-time jobs and to create 75 full-time jobs within Canada.
The amendment has been completed to increase the contribution amount from $173M to $200M. This is a partially repayable contribution.
The Strategic Innovation Fund (SIF) attracts and supports new high-quality business investments. In allocating funding, SIF looks to accelerate areas of economic strength, strengthen and expand the role of Canadian firms in regional and global supply chains, support economic strategies, and attract investment that creates new, good, well-paying jobs.